Nuvectis paid $40 million in upfront and near-term payments to buy exclusive worldwide ex-China rights to two Haisco Pharmaceutical assets, with biobucks that could reach $1.42 billion.
The lead asset is NXP100, an oral once-daily complement Factor B inhibitor currently under two regulatory reviews in China for paroxysmal nocturnal hemoglobinuria, a rare genetic blood disorder. It’s also running a Phase 3 trial for IgA nephropathy and has mid-stage data in lupus nephritis. The PNH market is projected to surpass $5 billion in 2026, dominated by AstraZeneca’s injectable C5 inhibitors Soliris and Ultomiris. Novartis’ Fabhalta is the only FDA-approved oral Factor B competitor, dosed twice daily. Nuvectis is betting NXP100’s once-daily schedule is the edge; in late-stage PNH trials, both candidates proved superior to C5 inhibitors with comparable results between them.
The second asset, NXP200, is an oral paradox-breaker BRAF inhibitor in Phase 1b for BRAF V600X-mutated and non-V600-mutated solid tumors, including colorectal cancer, melanoma, and non-small-cell lung cancer.
What does Nuvectis get for $40 million? A late-stage Factor B play in a $5 billion market, a next-gen oncology program, and a leap from Phase 1b to Phase 3 relevance. Before this deal, the company hadn’t advanced past Phase 1b: its prior lead program, NXP900, was a Phase 1b study in advanced cancers.
Haisco’s deal with AbbVie for pain medicine and a separate Eli Lilly collaboration were both inked in Q2 2026, making this Haisco’s third licensing deal of the quarter. China biopharma is exporting late-stage assets to Western buyers at pace; Haisco is among the busiest originators doing it.
The deal closes only after Nuvectis satisfies financing conditions, confirming it has enough capital to advance both programs.
— Diana Kowalski